Q-omics provides the consensus-scored ARSH profile across patient tissues and cancer cell-line models. ARSH expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ARSH is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, ARSH RNA expression shows 11,092 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, HNSC, and TGCT as cancer lineages where ARSH shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARSH — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARSH survival associations across molecular data types. ARSH RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARSH RNA expression–survival associations across cancer types. High ARSH expression shows unfavorable associations in ACC, DLBC and SKCM, but favorable associations in UVM, HNSC and ESCA. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ARSH RNA expression.
This table summarizes ARSH tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ARSH. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARSH shows lower tumor expression in HNSC and KIRC and higher tumor expression in LUAD, THCA, COAD and UCEC. The HNSC box plot shows higher ARSH RNA expression in normal versus tumor tissue (log2 FC = −0.332, t-test p < 0.001).
This table shows molecular features associated with ARSH in patient tissues and cancer cell lines. In patient samples, ARSH shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ARSH RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BREAST.
